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Fragment screening is widely used to identify attrac-
tive starting points for drug design. However, its
potential and limitations to assess the tractability of
often challenging protein:protein interfaces have
been underexplored. Here, we address this question
by means of a systematic deconstruction of lead-like
inhibitors of the pVHL:HIF-1a interaction into their
component fragments. Using biophysical techniques
commonly employed for screening, we could only
detect binding of fragments that violate the Rule of
Three, are more complex than those typically
screened against classical druggable targets, and
occupy two adjacent binding subsites at the inter-
face rather than just one. Analyses based on ligand
and group lipophilicity efficiency of anchored frag-
ments were applied to dissect the individual subsites
and probe for binding hot spots. The implications of
our findings for targeting protein interfaces by frag-
ment-based approaches are discussed.
INTRODUCTION
Protein-protein interactions (PPIs) are attractive targets for the
development of small molecule chemical probes and drugs.
However, targeting protein-protein interfaces with drug-like
small molecules of desired potency and physicochemical prop-
erties has remained a formidable challenge (Yin and Hamilton,
2005; Wells and McClendon, 2007). Some successes have
been achieved by targeting deep grooves on proteins that
accommodate alpha helical motifs; however, shallow and
featureless interfaces that lack buried pockets have been tradi-
tionally harder to target. Although ‘‘hot spots’’ can be identified
on either surface involved in the PPI by site-directed mutagen-
esis, these do not necessarily translate to hot spots for small
molecule binding. In fact, binding small molecules solely to
such hot spots does not always provide sufficient affinity for bio-
logical activity (Wells and McClendon, 2007; Kozakov et al.,1300 Chemistry & Biology 19, 1300–1312, October 26, 2012 ª2012 E2011). Furthermore, many interfaces appear to be highly adapt-
able in their ability to bind to different protein partners, often
using hidden cryptic pockets, but it is not well understood how
best to exploit these features for drug design. Because the
number and nature of protein-protein interactions successfully
targeted with small molecules has remained limited, it is impor-
tant to assess their tractability by discovering and properly
characterizing new ‘‘druggable’’ or ‘‘ligandable’’ binding sites
(Hajduk et al., 2005; Edfeldt et al., 2011; Fauman et al., 2011;
Surade and Blundell, 2012).
Fragment-based lead discovery (FBLD) is firmly established
as a powerful and efficient way to develop small molecule
binders of desired potency and physicochemical properties,
with notable successes targeting enzyme active sites (Erlanson
et al., 2004; Hajduk and Greer, 2007; Congreve et al., 2008;
Murray and Rees, 2009). There is increasing hope that FBLD
may provide new solutions to address difficult targets, including
PPIs, in part because of the limited success of more traditional
methods, including high-throughput screening (HTS), against
these difficult targets (Coyne et al., 2010; Crews, 2010). The
higher hit rates in screening, higher ligand efficiencies, and
greater sampling of chemical space that are afforded by smaller
fragments compared to larger compounds present in HTS
libraries are among the key features that make fragment-based
approaches highly attractive, provided that weak binding inter-
actions can be reliably detected (Ciulli and Abell, 2007). Frag-
ment screens are therefore typically performed experimentally
using sensitive biophysical techniques, such as NMR spectros-
copy, fluorescence-based and thermal methods, surface plas-
mon resonance, and X-ray crystallography, or computationally
using molecular docking (Ciulli et al., 2006; Teotico et al., 2009;
Larsson et al., 2011). On the other hand, some have posited
that nontraditional pharmaceutical targets, such as PPIs, would
be unlikely to be suitable for FBLD, partly because the small
aromatic fragments that enrich typical fragment libraries would
be expected to bind poorly to the flat, more solvent exposed,
and often dynamic protein surfaces (Hajduk et al., 2011).
Although this may seem a problem primarily of library design,
druggable pockets that would be suitable to accommodate
binding of small molecular fragments have indeed shown to be
either too small in size to achieve desired level of binding affini-
ties (Maurer et al., 2012; Sun et al., 2012) or highly cryptic, oftenlsevier Ltd All rights reserved
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covalent tethering (Erlanson et al., 2000), serendipitously (Sledz
et al., 2011), or by targeting mutational cavities (Basse et al.,
2010). Nevertheless, a few successes have been achieved by
targeting PPIs using fragment screening, such as in the cases
of the anticancer Bcl target family (Petros et al., 2006), interleu-
kins (Braisted et al., 2003), and the ZipA/FtsZ interaction (Tsao
et al., 2006). Many more examples will likely be reported in future
years, given the interest and promise of this area. However, the
field is still in its infancy, and the question of whether FBLD will
ultimately deliver more successes and compounds of better
physicochemical properties than other approaches to date
remains unanswered.
It was first observed byWells andMcClendon (2007) that high-
affinity inhibitors of PPIs, irrespective of the approach being used
to discover them, tend to have, on average, significantly lower
ligand efficiencies (LE 0.24 kcal mol1 NHA1, defined as
binding energy relative to number of heavy atoms NHA)
LE =
DG
NHA
=
RT InKd
NHA
(Hopkins et al., 2004) when comparedwith compounds targeting
enzyme active sites (LE 0.3–0.4 kcal mol1 NHA1) (Wells and
McClendon, 2007). Small molecules targeting PPIs that were
discovered by several approaches, including FBLD, have been
analyzed and found to be larger in size, to have higher lipophilic-
ity (as measured byCLogP), and to contain more rings and fewer
rotatable bonds on average than those for drugs and ligands tar-
geting active sites (Higueruelo et al., 2009; Morelli et al., 2011).
These in turn will likely result in poorer physicochemical and
pharmacological properties, including lower solubility, poorer
cell permeability, and nonspecific toxicity (Leeson and Spring-
thorpe, 2007). Therefore, not only it is important to identify drug-
gable hot spots at protein interfaces, it is also crucial to evaluate
their ability to yield high-affinity ligands while keeping molecular
weight and lipophilicity under control. For these purposes,
a metric called ligand lipophilic efficiency
LLEAT = 0:11+RT Inð10ÞpKd  cLogP
NHA
has been recently introduced by Astex Pharmaceuticals in order
to scale binding affinities by both size and lipophilicity in
a manner consistent with LE, thus enabling control of each
property during optimization (Mortenson and Murray, 2011).
However, this metric has not been extensively used to date
when assessing the ligandability of PPIs.
Here, we present a rigorous deconstructive fragment-based
study to probe the tractability of a model protein-protein inter-
face, that is, between the von Hippel-Lindau protein (pVHL)
and the alpha subunit of hypoxia-inducible factor 1 (HIF-1a)
(Jaakkola et al., 2001; Hon et al., 2002; Min et al., 2002). pVHL
is the substrate binding module of the VHL Cullin RING type E3
ubiquitin ligase (CRL2VHL), a multi-subunit complex composed
also of Elongin B, Elongin C, Cullin-2, and Rbx1. pVHL functions
to direct proteasomal degradation of HIF-1a under high oxygen
conditions; its critical role in cellular oxygen sensing and the
hypoxic response are well established, whereas many nonca-
nonical HIF-independent roles remain to be elucidated (Jaakkola
et al., 2001; Kaelin, 2008). The pVHL:HIF-1a interaction involvesChemistry & Biology 19, 1300–1recognition of a long, flexible region of HIF-1a and of a key post-
translational modification (proline hydroxylation). We recently
reported the computational design of lead-like small molecule
inhibitors of this PPI that mimic the structure of the HIF-1a
peptide (Buckley et al., 2012). This provided the starting point
for a model study to ask: could we have discovered these inhib-
itors using FBLD?What is theminimal complexity of fragments of
the inhibitors required to detect their binding? Can ‘‘hot spots’’
for preferential fragment targeting be identified at the protein
interface? In order to answer these questions, we structurally
and biophysically characterized three pVHL binders and modu-
larly fragmented them. Fragment binding was assessed using
biophysical methods widely employed in fragment screening.
Furthermore, we dissected the contribution of different groups
to the ligand binding free energy by applying ligand and group
lipophilicity efficiency metrics.
RESULTS
Crystal Structures of pVHL with Bound Small Molecule
Inhibitors
Crucial to a fragment-based deconstructive analysis of small
molecules targeting PPIs is the structural elucidation of the
ligand binding modes. We solved cocrystal structures of the
ternary complex pVHL-ElonginC-ElonginB (VCB, Figure 1A)
with a 19-amino-acid-long peptide from HIF-1a bound (Fig-
ure 1B; Figure S1 available online; see also Hon et al., 2002;
Min et al., 2002) and with three bound inhibitors that we recently
designed based on in silico modeling (1, Figure 1D; 2, Figure 1E;
and 3, Figure 1C [Buckley et al., 2012]; see also Figure 3A). The
structures revealed that the inhibitors fit snugly at the pVHL
surface and mimic many of the key interactions observed in
the pVHL:HIF-1a structure. The targeted binding site can be
schematically divided into three subsites: left-hand side (LHS),
central core, and right-hand side (RHS) (Figure 1A). The central
subsite is formed by several buried, mostly aromatic, residues
of pVHL, namely, W88, Y98, H110, S111, H115, and W117,
many of which are frequently mutated in VHL disease and
sporadic renal cell carcinomas (Kaelin, 2008). This subsite
recognizes trans-4-hydroxyproline (Hyp) in the most favored
C4-exo conformation of its pyrrolidine ring, with the Hyp hydroxyl
group forming two key hydrogen bonds to the side chains of
H115 and S111 and replacing a water molecule bound at this
position in the apo structure (Figure S1A) (Loenarz et al., 2009).
In addition, hydrogen bonds are present between the carbonyl
oxygen and the Y98 OH group and between the amide NH and
the His110 carbonyl. The ligands recapitulate the key interac-
tions observed between pVHL and Hyp564 of the HIF-1a binding
epitope. The LHS pocket is formed by two hydrophobic residues
(F91 and Y112) and three hydrophilic amino acids (H115, N67,
and R69). In addition, the LHS pocket contains a conserved
water molecule that is seen in all four structures. The crystal
structures show that the ligands’ LHS isoxazole group forms
a pp interaction with the Y112 side chain and hydrogen bonds
to this conserved water molecule, thereby recapitulating the
interaction made by the HIF-1a peptide epitope as a bioisostere
of the Leu562 carbonyl. The RHS subsite is an elongated pocket
defined mainly by hydrophobic amino acids, both at its entry
(I109, F76, Y98, and W117) as well as further away from the312, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1301
Figure 1. Structural Characterization of Small Molecules Targeting
the pVHL:HIF-1a Interactions
(A) General binding mode of small molecule inhibitors of pVHL:HIF-1a, based
on the crystal structure of the VCB ternary complex with 1 bound, as shown in
(D). The small molecule is shown in stick representation, the left-hand side
(LHS) and right-hand side (RHS) groups are shown as green and red spheres,
respectively, as represented in the model structure below. VCB is shown in
surface representation (pVHL in green, Elongin C in gold, and Elongin B in
purple).
(B–E) Crystal structures of VCB in complex with a 19-mer HIF-1a peptide
(DEALAHypYIPMDDDFQLRSF) (B), 3 (C), 1 (D), and 2 (E) are shown with the
ligands as stick representation bound on the surface of pVHL (green). Resi-
dues in the HIF-1a binding site of pVHL are shown in magenta in stick repre-
sentation. Residues are labeled in (C).
See also Figure S1 and Table S1.
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show that the ligands’ phenyl rings are involved in a side-on
interaction with the Y98 phenol. A comparison of the bound
structures of 1–3 demonstrates a degree of the plasticity of the
RHS pocket of pVHL. The R107 side chain moves out to accom-
modate larger hydrophobic RHS substituents, as in the case of
the biphenyl group of 2 (Figure 1E). Unlike in the case of 2, the
RHS oxazole group of 3 hydrogen bonds to the R107 NH2 as
does the p-methylester group of 1 (Figures 1C–1D). In addition
the CH at position 2 of the oxazole ring of 3 is hydrogen bonded
to the P99 backbone carbonyl.
Biophysical Characterization of Inhibitors of the
pVHL:HIF-1a Interaction
To characterize fully the binding of the inhibitors to VCB, we em-
ployed four different biophysical techniques:1302 Chemistry & Biology 19, 1300–1312, October 26, 2012 ª2012 E(1) Differential scanning fluorimetry (DSF) to monitor protein
thermal shifts in the presence of the dye Sypro Orange
due to ligand-induced protein stabilization (Kranz and
Schalk-Hihi, 2011);
(2) One-dimensional ligand-observed 1H NMR spectros-
copy, including STD (Mayer and Meyer, 1999) and Water-
LOGSY (Dalvit et al., 2001) experiments that monitor
changes in ligand signals in the presence of protein due
to cross-relaxation, after selective excitation of protein
or water signals, respectively, and relaxation-edited
Carr-Purcell-Meiboom-Gill (CPMG) experiments that
allow monitoring of broadened bound ligand signals in
the presence of the protein;
(3) A fluorescence polarization (FP) assay to monitor the
concentration-dependent displacement of the fluores-
cent HIF-1a peptide, FAM-DEALAHypYIPD (Kd = 560 nM
by FP) (Buckley et al., 2012); and
(4) Isothermal titration calorimetry (ITC) to directly monitor
the thermodynamic parameters of ligand binding (Ciulli
et al., 2006).
Representative data for complete biophysical characterization
of inhibitor 1 are shown in Figure 2 (in Figure S3 for 2 and 3), and
results for 1–3 are summarized in Table 1. The ligands exhibited
binding in all four binding assays. Binding was not detected for 4,
an analog of 1 lacking the pyrrolidine hydroxyl group (Fig-
ure S3). This is consistent with the loss of binding of nonhydroxy-
lated relative to hydroxylated HIF-1a peptides, supporting the
hydroxyl’s critical role in HIF-1a recognition by pVHL (Hon
et al., 2002). Our current best inhibitor 3 has a Kd of 5 mM,
a molecular weight of 410 Da, and low lipophilicity (ClogP =
0.05), placing it in the lead-like range and resulting in good
ligand efficiency and ligand lipophilicity efficiency (LE and LLEAT
both 0.24 kcal mol1 NHA1; Table 1). The latter compare very
well with the average LE of 0.24 kcal mol1 NHA1 observed
by Wells and McClendon (2007) for optimized fragments and
inhibitors of a range of different PPIs. In addition, it exhibits
high aqueous solubility (up to 2 mM in buffer at pH 7.0) and is
Rule of 5 compliant (Table 2). Taken together, these results
provided us with attractive starting points and a robust platform
for a fragment deconstruction model study.Fragmentation of Inhibitors I: Fragments Targeting
a Single Subsite
With the structural and biophysical characterization of small
molecule inhibitors of the pVHL:HIF-1a interaction established,
we turned to the key question of whether these compounds
could have been discovered by a fragment-based approach.
We first screened a small library of fragments that occupy the
individual LHS, central core, and RHS subsites as part of inhibi-
tors 1–3 (Figure 3A). Included in the library were: (1) the free
carboxylate and the i-propylamide derivatives of the methyl-iso-
xazole LHS fragment (5–6); (2) the 4-substituted free amines and
corresponding acetylated derivatives of the aromatic RHSmeth-
ylbenzoate, biphenyl, and phenyl-oxazole fragments (7–12); and
(3) the free L-Hyp amino acid and its neutral derivative capped on
both ends, N-acetyl-Hyp-N-methyl (13) that bind at the central
core subsite. These fragments range in size between 10 and
17 NHAs and comply with the Rule of Three (Ro3, Table 2)lsevier Ltd All rights reserved
Figure 2. Biophysical Characterization of
Compound 1 Binding to VCB
(A) WaterLogsy, STD, and CPMG NMR spectros-
copy.
(B) Isothermal titration calorimetry.
(C) Fluorescence polarization.
(D) Differential scanning fluorimetry.
See also Figure S3.
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Property Definitions (http://www.ebi.ac.uk/chemblntd/glossary).
To monitor fragment binding, we initially selected DSF, NMR
spectroscopy, and FP as these techniques are widely used for
first-line screening of fragment libraries (Ciulli and Abell, 2007).
Fragments were tested at concentrations typically employed in
these assays, that is, 5 mM for DSF, 1 mM for the three ligand-
observed NMR experiments, and starting at 10 mM in 2-fold
dilution dose response curves in competition with the HIF-1a
peptide for FP. Surprisingly, we were unable to unambiguously
detect fragment binding directly in any of these experiments
(Figure S2). In order to confirm our findings, we also assessed
the ability of the fragments to displace ligand 1 in competitive
NMR experiments, by monitoring the STD and WaterLOGSY
signals of 0.25 mM of 1 binding to VCB in the presence and
absence of 1 mM of fragments 5–13. None of the fragments
showed any evidence of competition with 1 in these experiments
(data not shown). As the LHS and RHS fragments occupy
nonoverlapping subsites in the inhibitors bound crystal struc-
tures, we then asked whether positive cooperativity between
fragments could enhance their individual binding affinities. We
therefore tested them in pairs using NMR spectroscopy and
DSF to interrogate the possibility of detecting their simultaneous
binding at adjacent sites (Figure S2). Again in this case, we wereChemistry & Biology 19, 1300–1312, October 26, 2012 ªnot able to detect binding under the
experimental conditions used.
Of all the fragments tested only 13
showed a very weak signal in the CPMG
and WaterLOGSY NMR spectra (13%
loss of CPMG signal and 1% LOGSY
signal but no STD signal, Table 1).
However, we could not detect any
binding of 13 by DSF, FP, or competitive
NMR, suggesting we would have missed
this fragment if it had been present in
a biophysical screen conducted under
these conditions. We were also unable
to detect any binding of 13 using a direct
ITC experiment. On the other hand, minor
perturbations of a control HIF-1a peptide
ITC titration were seen when 13 was
preincubated with VCB at 5 and 10 mM
concentrations (Figure S3, resulting in
a back-calculated Kd of 10 mM
using a competitive binding model, see
Supplemental Experimental Procedures).
Encouraged by these results supporting
binding of 13, albeit weak, we set out to
soak it at 25 mM concentration intoprotein crystals and could identify clear electron density corre-
sponding to the ligand, confirming the expected binding mode
(Figure 4; Figure S1).
Fragmentation of Inhibitors II: Fragments Targeting
More than One Subsite
To address the question of which size and structural complexity
would be required to detect and characterize fragment binding,
we expanded the promising fragment 13 toward either ends of
the protein interface (Figure 3B). Larger fragments of the initial
inhibitor 1 were synthesized that contained the Hyp core frag-
ment and either a phenyl or p-methylbenzoate group at RHS
(14 and 16), a methyl-isoxazole group at LHS (15) or both phenyl
and methyl-isoxazole groups on the same compound (17). Frag-
ments 14–17 exhibited NHAs ranging from 19 to 25, MW
between 262 and 343 Da, ClogP < 0.2, 2 hydrogen bond donors,
3–5 hydrogen bond acceptors, and 2–4 rotatable bonds (Fig-
ure 3B; Table 2). They therefore approach the limits of, and in
most cases violate, the Ro3. Evidence of binding of 14, the
only Ro3 compliant fragment, was only observed by NMR but
not by DSF and FP (Table 1; Figure S3). In contrast, we were
able to detect binding of the LHS-core fragment 15 and of the
core-RHS fragment 16 in DSF and NMR, and to characterize
their binding affinities by FP and ITC (Table 1; Figure S3). Taken2012 Elsevier Ltd All rights reserved 1303
Table 1. Biophysical Characterization of Small Molecules Binding to VCB
Compound
NMR Spectroscopy DSF FP ITC LE LLEAT
Signal Monitored
(ppm)
CPMG
(% loss)
STD
(% of 1D)
LOGSY
(% of 1D) DTm (
C) Kd (mM) Kd (mM) DG (kcal/mol) DH (kcal/mol)
TDS
(kcal/mol)
(kcal mol1
NHA1)
(kcal mol1
NHA1)
3
Isox arom 6.23 15 3.2 2.6 4.5 ± 0.0 12.5 ± 0.1 5.43 ± 0.22 7.19 ± 0.02 6.84 ± 0.05 0.35 ± 0.05 0.24 0.24
Hyp core
13
Acetyl 2.13 13 0 1.0 1.4 ± 0.4 NB Kdz 10,000a 0.21 0.40
14
Acetyl 2.13 45 2.0 3.1 0.2 ± 0.0 NB ND ND ND
RHS1 Ref
15
Isox arom 6.27 53 4.5 8.0 2.1 ± 0.4 660 ± 15 242a 4.94a 5.76a 0.82a 0.24 0.36
LHS Ref
16
OMe 3.94 26 3.2 2.1 1.7 ± 0.4 150 ± 2 270 ± 4 4.88 ± 0.01 4.35 ± 0.02 0.53 ± 0.02 0.21 0.21
RHS2 Ref
17
Isox arom 6.26 36 3.6 1.5 1.4 ± 0.0 295 ± 3 600 ± 17 4.40 ± 0.02 12.20 ± 0.20 7.80 ± 0.20 0.18 0.17
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Table 1. Continued
Compound
NMR Spectroscopy DSF FP ITC LE LLEAT
Signal Monitored
(ppm)
CPMG
(% loss)
STD
(% of 1D)
LOGSY
(% of 1D) DTm (
C) Kd (mM) Kd (mM) DG (kcal/mol) DH (kcal/mol)
TDS
(kcal/mol)
(kcal mol1
NHA1)
(kcal mol1
NHA1)
LHS
18
OMe 3.93 39 9.2 5.4 4.5 ± 0.7 53.2 ± 0.7 45.5 ± 2.6 5.93 ± 0.04 3.42 ± 0.12 2.51 ± 0.12 0.21 0.12
19
OMe 3.94 70 11.1 2.1 0.5 ± 0.3 165 ± 7 280 ± 10 4.85 ± 0.02 1.89 ± 0.04 2.96 ± 0.04 0.17 0.08
20
OMe 3.93 55 9.3 0 0.5 ± 0.0 580 ± 14 665a 4.34a 5.90a 1.55a 0.15 0.13
1
OMe 3.93 29 9.4 5.5 2.3 ± 0.0 86.1 ± 1.6 96.2 ± 4.6 5.48 ± 0.03 9.99 ± 0.22 4.51 ± 0.22 0.19 0.18
RHS1
21
Isox arom 6.27 19 1.1 2.0 0.2 ± 0.3 1,106 ± 21 ND 0.17 0.16
17
Isox arom 6.26 36 3.6 1.5 1.4 ± 0.0 295 ± 3 600 ± 17 4.40 ± 0.02 12.20 ± 0.20 7.80 ± 0.20 0.18 0.17
22
Isox arom 6.24 18 1.2 5.1 0.5 ± 0.0 452 ± 6 435 ± 8 4.59 ± 0.01 8.65 ± 0.09 4.06 ± 0.08 0.18 0.25
23
Isox arom 6.26 57 2.6 6.9 0.9 ± 0.0 343 ± 4 350 ± 17 4.72 ± 0.03 8.13 ± 0.22 3.41 ± 0.02 0.19 0.27
(Continued on next page)
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Table 1. Continued
Compound
NMR Spectroscopy DSF FP ITC LE LLEAT
Signal Monitored
(ppm)
CPMG
(% loss)
STD
(% of 1D)
LOGSY
(% of 1D) DTm (
C) Kd (mM) Kd (mM) DG (kcal/mol) DH (kcal/mol)
TDS
(kcal/mol)
(kcal mol1
NHA1)
(kcal mol1
NHA1)
RHS2
24
Isox arom 6.26 55 3.4 4.1 1.4 ± 0.0 821 ± 12 ND 0.14 0.05
2
Isox arom 6.26 70 19 19 5.5 ± 0.0 27.7 ± 0.2 ND 0.20 0.11
25
Isox arom 6.24 28 3.5 4.7 3.2 ± 0.0 20.3 ± 0.5 14.9 ± 0.8 6.59 ± 0.03 4.84 ± 0.06 1.75 ± 0.06 0.21 0.18
26
Isox arom 6.23 15 1.3 5.1 6.8 ± 0.0 3.6 ± 0.1 7.35 ± 0.36 7.01 ± 0.03 5.62 ± 0.05 1.39 ± 0.06 0.23 0.23
ND, not determined; NB, no binding. See also Figure S4 and Table S2.
aThese data were obtained in a competitive ITC assay.
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Table 2. Physicochemical Properties of Inhibitors 1–3 and Fragments 5–17
Inhibitors
Properties (Ro5) 1 2 3
MW (%500 Da) 401 419 410
cLogP (%5) 0.14 2.06 0.05
HBD (%5) 2 2 2
HBA (%10) 7 5 7
Rot. bonds (%5) 5 5 5
Ro5 compliant ✔ ✔ ✔
NMR ✔ ✔ ✔
DSF ✔ ✔ ✔
ITC ✔ ✔ ✔
FP ✔ ✔ ✔
Fragments
Properties (Ro3) 13 5 6 7 8 9 10 11 12 14 15 16 17
NHA 13 13 10 12 15 14 17 13 16 19 19 23 25
MW (%300Da) 186 182 141 165 207 183 225 174 216 262 267 320 343
cLogP (%3) 1.84 0.22 0.34 1.06 0.92 2.98 2.84 0.87 0.73 0.04 1.71 0.01 0.17
HBD (%3) 2 1 1 1 1 1 1 1 1 2 2 2 2
HBA (%3) 3 2 3 2 2 1 1 1 2 3 5 5 5
Rot. bonds (%3) 0a 3 2 2b 3b 2 3 2 3 2a 2a 4a 4a
PSA (%60) 69.6 50.7 64.7 52.3 55.4 26.0 29.1 47.6 50.7 69.6 91.2 95.9 91.2
Ro3 compliant ✔c ✔ ✔c ✔ ✔ ✔ ✔ ✔ ✔ ✔c ✘ ✘ ✘
NMR ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✔ ✔ ✔
DSF ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✔ ✔
FP ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✔ ✔
ITC ✘ - - - - - - - - - ✔ ✔ ✔
✔, yes or true; ✘, not or false.
aThe C(a)C(O) bond of the Hyp core, about which rotation is described by the Ramachandran c dihedral angle, was not counted as a rotatable bond.
bThe C(O)O bond of the methyl ester was not counted as a rotatable bond.
cNot considering the requirement for PSA.
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the starting inhibitors to form favorable interactions in at least
two subsites of the pVHL-HIF-1a interface. This was confirmed
by the ability to detect and fully characterize the binding of two
dipeptides derived from HIF-1a, Ala-Hyp, and Hyp-Tyr (Fig-
ure S2). Compound 17, spanning the three subsites LHS-Hyp-
RHS, also yielded binding data across the full spectrum of
biophysical techniques.
Fragmentation of Inhibitors III: Deconstructing Ligand
and Group Efficiencies
With the first two questions addressed, we asked whether we
could identify preferential ‘‘hot spots’’ for fragment binding at the
protein interface. The lack of quantitative binding for the smaller
fragments 5–13 meant that an indirect approach was needed to
tackle this problem. As binding of 15, 16, and 17 could be reliably
characterized biophysically, these were chosen as reference
compounds to anchor fragments covalently in order to study their
contributions tobindingat threedistinct subsites, LHS,RHS1, and
RHS2 (Figure3).We thusdesigneda libraryof 12compounds (1,2,
and 17–26) each containing a small probe fragment, either t-butyl,
phenyl, pyridyl, orMe-(is)oxazole, attached to theappropriate side
of each reference compound (Figure 3C). These groups wereChemistry & Biology 19, 1300–1chosen as they had (1) similar size (4–6 NHAs) and would be suffi-
ciently small to fit in each subsite of the interface; (2) different
values of CLogP ranging from 0.6 to 3.1; and (3) different shapes.
Binding of compounds 17–26 was fully characterized by all four
biophysical techniques (see Figure S3 and results summarized
in Table 1). A good correlation was seen between the Kd values
measured directly by ITC and those back calculated from the
IC50 values measured by FP (Table 1; Figure S4), justifying their
use in cases in which ITC data could not be obtained (in other
cases the average Kd value was used to calculate DGs).
In order to quantify and dissect the contributions of each
group at each individual subsite, we measured their group effi-
ciency (GE), defined as binding energy per heavy atomof a group
of the molecule
GE =
DDG
DNHA
:
GE scales affinity by size in a fashion consistent with ligand
efficiency, with a value of 0.3 kcal mol1 NHA1 usually taken
as a reference threshold (Congreve et al., 2008). To take into
account not only size but also lipophilicity, we also calculated
ligand lipophilicity efficiency (LLEAT) and group lipophilicity effi-
ciency (Mortenson and Murray, 2011)312, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1307
Figure 3. Small Molecule Library Used to
Probe the pVHL:HIF-1a Interaction
(A) Micromolar small molecule inhibitors 1–3 used
for the biophysical and structural characterization
of the pVHL:ligand interactions and fragments
used to probe individual subsites.
(B) Fragments designed to probe more than one
subsite, including reference molecules used to
calculate group efficiencies and group lipophilicity
efficiencies.
(C) Library of compounds placing a t-butyl, phenyl,
pyridyl, or Me-(is)oxazole group at the left-hand
site (LHS), right-hand site 1 (RHS1), or 2 (RHS2).
ClogP values are not defined for groups and
depend on the context of the whole molecule. The
values listed were calculated for parent molecules
containing a methyl attached to each group.
See also Figure S2.
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DNHA
:
For consistency, both metrics have been designed to have the
same reference value of 0.3 kcal mol1 NHA1 as LE and GE,
respectively, hence providing meaningful comparisons between
them.
Compounds exhibited LE values ranging from 0.14 to 0.24
(Table 1, average LE = 0.19 ± 0.03 kcal mol1 NHA1). Taking lip-
ophilicity into account, the differences between the ligands
become more pronounced, with LLEAT ranging from as little
as 0.05 for 24 up to 0.36 for 15 (Table 1, average LLEAT
0.19 ± 0.09 kcal mol1 NHA1), reflecting the wide range of
lipophilicities introduced by the chosen groups. Despite the
challenges we faced at detecting and measuring binding of the
capped Hyp 13, its small size (NHA = 13) and hydrophilic nature
(ClogP = –1.8) result in the highest LLEAT (0.40) across the series
based on an estimated Kd of 10mM from competition ITC exper-
iments. The group-based parameters are on average much
lower in value than the corresponding ligand-based parameters,
indicating that the groups are not able to maintain the level of
ligand efficiencies observed with 3 and reference compounds
15–17. However, group efficiencies are spread over a wider
range (Figure 5A, average GE = 0.07 ± 0.23 and average GLEAT =
0.13 ± 0.43) and hence provide a more informative set of
parameters to monitor than ligand based efficiencies to probe
the individual subsites.
Dissecting Hot Spots of Fragments Targeting Individual
Subsites
As binding could not be measured for any fragment lacking the
central Hyp core, we can only estimate the group efficiencies
of 13 based on a DG of 2.8 kcal/mol associated to its Kd of1308 Chemistry & Biology 19, 1300–1312, October 26, 2012 ª2012 Elsevier Ltd All rights res10 mM as determined by competitive
ITC. To bring the contributions of 13 as
a group onto the same scale as the corre-
sponding terms for other groups, the
rigid-body barrier to binding, estimated
to be +4.2 kcal/mol (Murray and Verdonk,
2002), was subtracted from the freeenergy of binding of 13 as previously described (Saxty et al.,
2007). Although this value is widely used, it can vary depending
on the types of interactions formed. Indeed, others have re-
ported values in the range of 6–12 kcal/mol for this term (Page
and Jencks, 1971; Lundquist and Toone, 2002); hence, we
may be underestimating the magnitude of the correction due
to the entropic barrier. This analysis yielded the largest group-
based values for 13 (GE = 0.53, GLEAT = 0.72), reinforcing its
role as a good anchoring fragment and defining the core subsite
as the hot spot that contains the bulk of the binding energy.
Group efficiencies calculated for the LHS isoxazole (GE = 0.08)
and the RHS methylbenzoate (0.09), biphenyl (0.14), and
phenyl-oxazole (0.21) correspond to DDGs of 0.9, 1.6, and
2.3 kcal/mol, respectively. These values are all much smaller
than the rigid-body barrier to binding, therefore allowing a retro-
spective rationalization of why the starting LHS and RHS frag-
ments 5–12 did not bind.
To analyze all the group contributions, we clusteredGEswithin
each subsite, allowing comparison of how each individual
subsite interacts with different fragments (Figure 5B, top). In
addition, we clustered GLEATs by the individual group, high-
lighting how each group probes the different subsites (Figure 5B,
bottom). The LHS subsite responded favorably to the binding of
the methyl-isoxazole group. The largest GE value, however, was
seen for the t-butyl group. This is in marked contrast to RHS1
and RHS2 that were more discriminating against this group,
highlighting the promiscuous nature of the solvent-exposed
LHS subsite. RHS2 appears to be a second hot spot for fragment
binding, as it exhibited the highest average GE value across the
group series (0.15). Importantly, all groups, except t-butyl, had
their highest GE and GLEAT at this subsite. This may be due to
a more pocket-like shape of RHS2, whereas the observed
flexibility of the R107 side chain may allow larger groups to beerved
Figure 4. X-Ray Crystal Structure of Fragment 13 Bound to VCB,
Solved at 2.50 A˚ of Resolution
Fragment 13 is shown in stick representation (magenta carbons), whereas
pVHL is shown in light yellow cartoon representation. Key amino acids inter-
acting with the fragment are shown in sticks, with carbon atoms in the same
color. The Fo-Fc omit electron density map associated with the fragment is
shown as a green mesh contoured at 3s. See also Figure S1.
Figure 5. Group Efficiencies and Group Lipophilic Efficiencies of
Small Molecules Binding to VCB
Values for GE (black) and GLEAT (red) for each group at the different positions
(LHS, RHS1, and RHS2) are listed in (A), and their distributions, according to
position or group, respectively, are shown in (B).
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substrate HIF-1a does not fully explore the binding potential of
this subsite as Ile566, despite being important for binding (Min
et al., 2002), is only partly buried in this pocket (Figure 1B). In
contrast to RHS2, RHS1 yielded negative, unfavorable GE values
for all groups tested, and the lowest average GE (–0.11), sug-
gesting it is the least ‘‘druggable’’ subsite. The poor GE of the
phenyl group is consistent with the weak binding shown by frag-
ment 14. It is possible that the best group is not among those
tested or that they are not accommodated for in their optimal
position due to conformational restriction provided by the meth-
ylene group linking RHS1 groups to the amide bond of Hyp. Our
results suggest that RHS1 could be a good place to concentrate
future medicinal chemistry optimization to improve the current
ligands, also given its role as a linker region between the two
identified hot spots, the core and RHS2 subsites.
DISCUSSION
Despite its rather modest affinity of 10 mM, the hydroxyproline
di-amide 13 contributes the most to the initial inhibitor binding
free energy. This becomes evident once this and the overall
ligand efficiency are corrected for the entropic rigid body barrier
to binding. Yet, this fragment could not be readily detected by
techniques routinely used for fragment screening. Similarly,
binding was not detected for any fragments targeting the LHS
or RHS pockets on pVHL, individually or in combinations. These
results were unanticipated because (1) it is often observed that
fragments have higher ligand efficiency than the larger
compounds they are part of, and (2) we would have expected
to detect binding of some of the fragments even if they had
only retained the ligand efficiency of the parent inhibitors (Table
S2). They also contrast with the results of a previous study in
which the binding of 19/22 fragments of nine known PPI inhibi-
tors of Bcl-xL was detected (Barelier et al., 2010). However, in
that case, the initial inhibitors were much larger than in our study
and included some that were discovered using FBLD, so detec-Chemistry & Biology 19, 1300–1tion of fragment binding was perhaps not surprising. Our results
point to the possibility that current fragment screens against
PPIs may be missing interesting fragments because of the inher-
ently low ligand efficiencies associated with binding small
molecules at protein surfaces. The pVHL:HIF-1a interaction
recapitulates many of the features of PPIs that appear to be
important in determining such low ligand efficiencies: (1) the
displacement of bound water molecules, as required with
binding of the Hyp core; (2) the exploration of cryptic pockets
at the protein surface, as in the case of the RHS2 pocket opening
upon conformational change of R107; and (3) the interaction
with subsites that the natural protein partner does not engage
with or does suboptimally, as in the case of Ile566 of HIF-1a.
These features would all contribute to low affinities of small,
unanchored fragments, preventing their detection in screens312, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1309
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weaker and less ligand efficient fragments (Kd z 10 mM, LE
0.2 kcal mol1 NHA1 as for the Hyp fragment 13) than those
typically found at enzyme active sites (Kd 0.1–1.0 mM, LE >
0.3 kcal mol1 NHA1), would still be useful starting points in
the construction of promising small molecules, as they can
generate much more interaction energy with the protein than
their modest affinities would lead one to suppose. This under-
scores the challenge of reliably detecting such weak but highly
specific interactions in screens while at the same time discrimi-
nating against nonspecific binding or artifactual effects. It further
highlights the importance of employing a range of orthogonal
screening strategies of sufficiently sensitive biophysical tech-
niques to allow robust identification of weak binders as hits
and their subsequent characterization and validation.
As fragments became more complex and began targeting at
least two subsites at the pVHL:HIF-1a interface rather than
a single one, we could unambiguously detect and characterize
their binding. Fragments 15 and 16 explore a higher level of
molecular complexity than the initial fragments 5–13, violate
the Ro3, and would have likely failed to pass filters commonly
applied to construct current fragment libraries. To this end,
a recent study has suggested that alleviating some of these strict
criteria can lead to higher hit rates of fragments and still identify
suitable starting points for future design (Ko¨ster et al., 2011).
Both 15 and 16 contain an aromatic ring attached to an amino
acid moiety. Similarly, we were able to measure binding of the
corresponding di-amino acid fragments. These observations
tempt us to speculate that aromatic/amino acid or di-amino
acid fragments that approach or break the limits of the Ro3 could
be privileged scaffolds against PPIs. Their inclusion in focused
fragment libraries aimed at targeting PPIs could lead to
increased hit rates from screens and could facilitate the identifi-
cation of novel binding sites. To this end, screens of a 1,300
commercially available Ro3-compliant fragment library have to
date proved unsuccessful in our experience against this PPI.
Taken together, our results suggest that the tractability of PPIs
may be a more complex feature than can be simply assessed
by screening of Ro3-compliant fragment libraries and point to
the need of sampling more complex chemical space.
In addition to askingwhether fragments of initial ligands can be
detected, one can ask whether ligands can always be parsed
into fragments that maintain the observed binding mode. This
question has been addressed for enzyme substrates and coen-
zymes (Stout et al., 1998; Ciulli et al., 2006), enzyme inhibitors
(Babaoglu and Shoichet, 2006; Nazare´ et al., 2012), and PPI
inhibitors (Barelier et al., 2010). It has been observed that smaller
fragments do not always recapitulate their binding mode as part
of the initial ligands. However, sufficiently elaborate fragments
often do so (Babaoglu and Shoichet, 2006; Barelier et al.,
2010). The results of our study are consistent with this observa-
tion, as binding of fragments could be detected only as they
became larger. As the Hyp core fragment 13 retains the binding
mode, it is reasonable to expect that the larger fragments 15–17
also do so.
To evaluate the contributions of the smaller fragments to the
binding free energy and to further rationalize our inability to
detect their binding, we anchored them around the Hyp core
and modularly deconstructed their ligand and group lipophilicity1310 Chemistry & Biology 19, 1300–1312, October 26, 2012 ª2012 Eefficiencies. To our knowledge, this study reports the first
example of using GE and GLEAT together to probe interactions
of fragments at distinct subsites of a PPI. In addition, this
approach can guide the design of PPI ligands while preventing
them from becoming too large and lipophilic. Optimization
programs that solely make use of LE or GEmetrics as guidelines
would favor hydrophobic binders bearing undesired physico-
chemical properties. On the other hand, LLEAT and GLEAT would
favor hydrophilic binders that may not pass biological barriers.
The combination of both metrics is therefore proposed as
a balanced guide to compound optimization and is being used
to develop improved inhibitors of the pVHL:HIF-1a interaction.
In summary, we report, to our knowledge, the first, compre-
hensive deconstructive study of known inhibitors of a protein-
protein interaction into fragments. Our group analysis, based
on thorough biophysical and structural characterization, demon-
strates how a fragment-based approach can be used to
dissect binding hot spots, analyze their key features, and ratio-
nalize fragment contributions at protein-protein interfaces. We
therefore provide a general methodology that can be applied
to characterize other protein-protein interactions and their small
molecule binders. Perhaps more importantly, the observations
emerged from our study of the pVHL:HIF-1a interaction could
prove useful in addressing the challenges faced when interro-
gating the ligandability of other difficult PPI targets by frag-
ment-based approaches.
SIGNIFICANCE
We have presented a deconstructive study of fragments
of a protein-protein interface (PPI) inhibitor. Over the past
15 years, fragment-based lead discovery (FBLD) has estab-
lished itself as a powerful approach to develop small
molecule binders of desired potency and physicochemical
properties. It is anticipated that FBLD may address the
well-documented failures of, for example, high-throughput
screening against more challenging targets, such as PPIs
(Murray et al., 2012). However, the potential and limitations
of biophysical fragment screening to assess the tractability
of PPIs have been underexplored. Our findings point to the
possibility that screening Rule of Three compliant libraries
may result in missing highly group-efficient and useful
fragments, as they could bind too weakly to be detected.
We therefore propose that the most fruitful fragments to
screen against PPIs should be somewhat larger than those
commonly used for more druggable targets and could
include ‘‘privileged’’ structures, such as aromatic-amino
acid hybrid compounds.
The model system investigated, that is, the interaction
between the von Hippel Lindau protein (pVHL) and the alpha
subunit of hypoxia-inducible factor 1 (HIF-1a), involves
recognition of a flexible peptide lacking secondary structure
and of a posttranslational modification. There is increasing
evidence that these features render a PPI more ligandable
than, for example, obligate PPIs involving large and flat
interfaces (Surade and Blundell, 2012), and that these types
of PPIs are providing new therapeutic opportunities (Filippa-
kopoulos et al., 2010). Given its many important biological
roles as a tumor suppressor protein and as an E3 ligase inlsevier Ltd All rights reserved
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development of small molecule therapeutics and probes.
The methodology reported here, integrating GE and GLE
analyses to dissect fragment binding, will guide the optimi-
zation of future pVHL ligands and can be applied to probe
hot spots at other PPIs.
EXPERIMENTAL PROCEDURES
VCB and VCBHCloning, Expression, Purification, and Crystallization
The pVHL:ElonginC:ElonginB (VCB) complex was expressed, purified, and
crystallized as previously described (Buckley et al., 2012). In order to purify
the complex between VCB and a 19-mer HIF-1a peptide (DEALAHypYIP
MDDDFQLRSF) (VCBH), VCB was mixed with a 2-fold excess of the peptide.
The excess of peptide was subsequently removed using a Superdex75 10/300
GL column, equilibrated in 20 mM Bis-Tris (pH 7.0), 150 mM NaCl, and 1 mM
DTT. VCBH was crystallized in 0.1 M K phosphate (pH 6.6), 0.2 M (NH4)2SO4,
20% PEG MME 5000, and 5 mM DTT, at 296 K, using hanging drop vapor
diffusion.
X-Ray Diffraction, Data Collection, and Crystal Structures Solution
X-ray data collection, structure solution, and refinement parameters for VCB-3
liganded structure were described previously (Buckley et al., 2012). Details
of the data collection and structure determination of VCB-1, VCB-2, VCB-
13, and VCBH structures can be found in Supplemental Experimental
Procedures.
Differential Scanning Fluorimetry
DSF experiments (Kranz and Schalk-Hihi, 2011) were performed using aRoche
Lightcycler 480 machine, in a 96-well plate setup, using 100 ml per well.
Compounds were assayed at 1 mM concentration (or 5 mM for fragments
targeting one subsite) in triplicates, using a concentration of 5 mM VCB in
100 mM Tris (pH 8.5), 100 mM NaCl, 2.53 Sypro Orange, and 5% v/v
DMSO. Data were recorded during a continuous scan from 37C to 95C.
The fluorescence excitation and emission wavelengths were 483 and 533 nm.
NMR Spectroscopy
1H NMR spectroscopic experiments were performed at 278 K on a 700 MHz
Bruker NMR spectrometer equipped with a 5 mm triple TXI cryoprobe with
z gradients. The resulting spectra were analyzed using the Bruker TopSpin
software. For direct binding experiments, each compound was run as three
samples, made up to 200 ml in 3 mm capillaries, according to the following
compositions (Trimethylsilyl-propionic acid-d4 [TSP] was present in all
samples for calibration purposes): (1) Control sample = 1 mM compound,
2% (v/v) d6-DMSO, 20 mM TSP, 50 mM NaPO4 (pH 7.0), and 10% (v/v) D2O;
(2) + protein sample = control sample + 10 mM VCB complex; (3) + protein +
displacer sample = control sample + 10 mM VCB complex + 500 mM HIF-1a
10-mer peptide (DEALAHypYIPD). For competition binding experiments,
each sample contained 0.25 mM of 1, 10 mM protein in the same buffer condi-
tions as above, and in the absence or presence of 1 mM fragments 5–13. More
detailed information on the pulse sequences used in the WaterLOGSY, STD,
and CPMG experiments can be found in Supplemental Experimental
Procedures.
Fluorescence Polarization
Fluorescence polarization measurements were recorded on a BMG LABTECH
PHERAstar Plus instrument as described in Supplemental Experimental
Procedures. The fluorescence excitation and emission wavelengths were
485 and 520 nm. Data were fitted using GraphPad Prism 5. Kd values for the
compound-VCB interaction were back-calculated from the measured IC50
values as described in Supplemental Experimental Procedures.
Isothermal Titration Calorimetry
ITC experiments were performed on an ITC200 instrument from Microcal Inc.
(GE Healthcare, Waukesha, WI, USA) at 25C as described in Supplemental
Experimental Procedures.Chemistry & Biology 19, 1300–1Synthetic Procedures
Detailed information on synthetic procedures is in Supplemental Experimental
Procedures.ACCESSION NUMBERS
The atomic coordinates and structure factors of the Homo sapiens
pVHL54-213:ElonginC:ElonginB in complex with 1 (2.79 A˚), 2 (2.65 A˚), 3 (2.90 A˚),
and 13 (2.5 A˚) and the HIF-1a peptide DEALAHypYIPMDDDFQLRSF (1.73 A˚)
have been deposited in the Protein Data Bank (PDB) with accession codes
3ztd, 3ztc, 3zrc, 4awj, and 4ajy, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, four figures, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chembiol.2012.08.015.
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